Search alternatives:
side decrease » sizes decrease (Expand Search), fid decreased (Expand Search)
step decrease » sizes decrease (Expand Search)
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), nn decrease (Expand Search)
side decrease » sizes decrease (Expand Search), fid decreased (Expand Search)
step decrease » sizes decrease (Expand Search)
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), nn decrease (Expand Search)
-
281
-
282
-
283
-
284
-
285
-
286
-
287
-
288
-
289
-
290
-
291
The RehaGait® system.
Published 2025“…Step height was normalized postoperatively; all other variables remained significantly worse than the HI. …”
-
292
Flow chart of included patients and dropouts.
Published 2025“…Step height was normalized postoperatively; all other variables remained significantly worse than the HI. …”
-
293
Dataset of the analyzed data.
Published 2025“…Step height was normalized postoperatively; all other variables remained significantly worse than the HI. …”
-
294
Table_1_FMT intervention decreases urine 5-HIAA levels: a randomized double-blind controlled study.DOCX
Published 2024“…However, in the placebo group, GSRS, CARS, and SRS scores showed no significant changes, while ABC scores decreased from 72 to 58.75 (p = 0.034). …”
-
295
-
296
-
297
-
298
-
299
Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”
-
300
Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”